Great Point Partners LLC Mirati Therapeutics, Inc. Transaction History

Great Point Partners LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$27.8 - $45.35 $2.4 Million - $3.91 Million	86,302 New	86,302 $3.76 Million
Q4 2022 Feb 14, 2023	BUY	$41.27 - $98.62 $5.49 Million - $13.1 Million	133,000 New	133,000 $6.03 Million
Q3 2021 Nov 15, 2021	SELL	$132.13 - $177.45 $13.2 Million - $17.7 Million	-100,000 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$144.0 - $179.73 $5.04 Million - $6.29 Million	-35,000 Reduced 25.93%	100,000 $16.2 Million
Q1 2021 May 17, 2021	BUY	$158.92 - $221.61 $21.5 Million - $29.9 Million	135,000 New	135,000 $23.1 Million
Q4 2019 Feb 14, 2020	SELL	$70.76 - $128.86 $21.2 Million - $38.7 Million	-300,000 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$59.49 - $104.71 $17.8 Million - $31.4 Million	300,000 New	300,000 $0

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Great Point Partners LLC, based on Form 13F filings with the SEC.

Stay updated on Great Point Partners LLC with notifications on news.